SUTRO BIOPHARMA, INC. Net Income Loss

Quick Answer

SUTRO BIOPHARMA, INC. reported Net Income Loss of -$191.09 million for the year ending 2025.

  • SUTRO BIOPHARMA, INC. showed an increase of +16.0% in Net Income Loss from 2024 to 2025.
  • This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Net Income Loss has declined by 11,327.1%.
  • Historical annual values: Fiscal year 2025: -$191.09 million | Fiscal year 2024: -$227.46 million | Fiscal year 2023: -$106.79 million | Fiscal year 2022: -$119.20 million | Fiscal year 2021: -$105.54 million | Fiscal year 2020: -$32.13 million | Fiscal year 2019: -$119.20 million | Fiscal year 2018: -$35.32 million | Fiscal year 2017: -$19.69 million | Fiscal year 2016: $1.70 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: